BioTuesdays

Category - Markets

Q32 Bio Logo
Markets

Clear Street starts Q32 Bio at buy; PT $38

Clear Street initiated coverage of Q32 Bio (NASDAQ: QTTB) with a “buy” rating and price target of $38.00. The stock closed at $8.77 on September 25. Q32 Bio is a clinical-stage biotechnology company developing therapies...

September 28, 2026
LENSAR Logo
Markets

Lucid starts Lensar at buy; PT $11

Lucid Capital Markets initiated coverage of Lensar (NASDAQ: LNSR) with a “buy” rating and price target of $11.00. The stock closed at $6.92 on September 25. Lensar designs, manufactures, and commercializes femtosecond...

September 28, 2026
Profound Medical Logo
Markets

Titan starts Profound Medical at buy; PT $12

Titan Partners initiated coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with a “buy” rating and price target of $12.00. The stock closed at $5.96 on Sept 10. Profound is a commercial-stage medical device company...

September 11, 2026
Zentalis Logo
Markets

Rodman & Renshaw starts Zentalis at buy; PT $11

Rodman & Renshaw initiated coverage of Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a “buy” rating and price target of $11.00. The stock closed at $4.50 on July 22. Zentalis is a clinical oncology innovator...

July 23, 2026
Equillium Logo
Markets

Clear Street starts Equillium at buy; PT $9

Clear Street initiated coverage of Equillium (NASDAQ: EQ) with a “buy” rating and price target of $9.00. The stock closed at $2.47 on July 20. Equillium is a clinical-stage biotechnology company developing therapies...

July 21, 2026
Perimeter Logo
Markets

Brookline starts Perimeter at buy; PT C$1.54

Brookline Capital Markets initiated coverage of Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) with a “buy” rating and price target of C$1.54 (US$1.11). The stock closed at C$0.32 on July 13. In March 2026...

July 14, 2026
Markets

Rodman & Renshaw starts Atossa at buy; PT $12

Rodman & Renshaw initiated coverage of Atossa Therapeutics (NASDAQ: ATOS) with a “buy” rating and price target of $12.00. The stock closed at $2.28 on July 6. Atossa, a clinical-stage biopharmaceutical company...

July 7, 2026